Michael Hallek
Overview
Explore the profile of Michael Hallek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
560
Citations
20772
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Braun T, Rade M, Merz M, Klepzig H, Grosse F, Fandrei D, et al.
Nat Med
. 2025 Feb;
PMID: 39984633
Chimeric antigen receptor (CAR) T cells and bispecific T cell engagers have become integral components in the treatment of relapsed/refractory multiple myeloma. We report a 63-year-old male who received ciltacabtagene...
2.
Pralong A, Simon S, Holtick U, Reimer A, Schoerger B, Kaur S, et al.
Ann Hematol
. 2025 Feb;
104(1):741-751.
PMID: 39920423
Patients treated with an allogeneic hematopoietic stem cell transplantation (allo-SCT) face a significant mortality risk, which might trigger existential distress. We aimed to investigate how hematology health care professionals (HCPs)...
3.
Furstenau M, Robrecht S, Schneider C, Tausch E, Giza A, Ritgen M, et al.
Blood
. 2025 Jan;
PMID: 39883943
The phase 2 CLL2-BZAG trial tested a measurable residual disease (MRD)-guided combination treatment of zanubrutinib, venetoclax and obinutuzumab after an optional bendamustine debulking in patients with relapsed/refractory CLL. In total,...
4.
Hallek M
Am J Hematol
. 2025 Jan;
100(3):450-480.
PMID: 39871707
Disease Overview: Chronic lymphocytic leukemia (CLL) is the most frequent type of leukemia. It typically occurs in older patients and has a highly variable clinical course. Leukemic transformation is initiated...
5.
Arndt V, Doege D, Frohling S, Albers P, Algul H, Bargou R, et al.
J Cancer Res Clin Oncol
. 2025 Jan;
151(1):39.
PMID: 39825921
No abstract available.
6.
Richardson T, Schutte D, Kobbe G, Baermann B, Holderried T, Schmitz F, et al.
Blood Adv
. 2025 Jan;
9(6):1370-1375.
PMID: 39746178
No abstract available.
7.
8.
Schiewer V, Klein A, Dietz T, Labouvie H, Kusch M, Kerek-Bodden H, et al.
Z Evid Fortbild Qual Gesundhwes
. 2024 Dec;
192:42-48.
PMID: 39672694
Background: In the German health care system, the participation of patients (patient representatives) and the consideration of their perspectives in all phases of research and care are being increasingly demanded....
9.
Caspers A, Pralong A, Hallek M, Voltz R, Simon S, Eichenauer D
Hematol Oncol
. 2024 Dec;
43(1):e70021.
PMID: 39655715
No abstract available.
10.
Beielstein A, Izquierdo E, Blakemore S, Nickel N, Michalik M, Chawan S, et al.
Cell Rep Med
. 2024 Nov;
5(12):101830.
PMID: 39603243
Macrophages in the B cell lymphoma microenvironment represent a functional node in progression and therapeutic response. We assessed metabolic regulation of macrophages in the context of therapeutic antibody-mediated phagocytosis. Pentose...